Preventing diabetic complications: A primary care perspective

Paul Zimmet

Research output: Contribution to journalReview ArticleResearchpeer-review

13 Citations (Scopus)


While controlling cardiometabolic risk factors remains central to diabetes management, substantial disease burden persists despite intensive targeting of blood glucose, blood pressure and lipids. Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provide some new insights. As well as significant reduction in total cardiovascular disease events, especially among patients with marked atherogenic dyslipidaemia (low high-density lipoprotein (HDL) cholesterol and hypertriglyceridaemia), fenofibrate had preventive effects on microvascular outcomes, reducing laser treatment for retinopathy, progression of albuminuria, and non-traumatic amputations. These findings suggest re-evaluation of fenofibrate as an option for reducing the risk of diabetic vascular complications.

Original languageEnglish
Pages (from-to)107-116
Number of pages10
JournalDiabetes Research and Clinical Practice
Issue number2
Publication statusPublished - May 2009
Externally publishedYes


  • Cardiometabolic risk factors
  • Diabetes
  • Diabetic retinopathy
  • Fenofibrate
  • Preventive medicine

Cite this